Pathologic response and exploratory analyses of neoadjuvant-adjuvant versus adjuvant pembrolizumab (PEM) for resectable stage IIIb-IV melanoma from SWOG S1801

被引:10
作者
Patel, S. [1 ]
Othus, M. [2 ]
Wright, P. [3 ]
Hyngstrom, J. [4 ]
Lao, C. D. [5 ]
Truong, T-G. [6 ]
Chandra, S. [7 ]
Kendra, K. [8 ]
Devoe, C. [9 ]
Hegde, A. [10 ]
Mangla, A. [11 ,12 ]
Lowe, M. [13 ]
Buchbinder, E. [14 ]
Kirkwood, J. M. [15 ]
Sharon, E. [16 ]
Korde, L. [17 ]
Moon, J. [2 ]
Sondak, V. K. [18 ]
Ribas, A. [19 ]
Prieto, V. [20 ]
机构
[1] Univ Texas MD Anderson Canc Ctr Houston, Melanoma Med Oncol Dept, Houston, TX USA
[2] Fred Hutchinson Canc Res Ctr, Biostat, Seattle, WA USA
[3] Spectrum Hlth, Surg Oncol, Grand Rapids, MI USA
[4] Univ Utah Hlth, Surg Oncol, Huntsman Canc Inst, Salt Lake City, UT USA
[5] Univ Michigan, Dept Dermatol, Comprehens Canc Ctr, Ann Arbor, MI USA
[6] Kaiser Permanente Vallejo Med Ctr, Hematol & Oncol Dept, Vallejo, CA USA
[7] Robert H Lurie Canc Ctr Northwestern Univ, Div Hematol Oncol, Chicago, IL USA
[8] OSUCCC Ohio State Univ, Med Oncol, Comprehens Canc Ctr James, Columbus, OH USA
[9] Northwell Hlth Canc Inst, Med Oncol, Lake Success, NY USA
[10] Univ Alabama Birmingham, Hematol Oncol, Birmingham, AL USA
[11] Case Western Reserve Univ, Hematol & Oncol, Cleveland, OH USA
[12] Univ Hosp, Cleveland, OH USA
[13] Emory Univ, Surg, Atlanta, GA USA
[14] Dana Farber Canc Inst, Med Oncol Dept, Boston, MA USA
[15] UPMC, Melanoma Program, Hillman Canc Ctr, Pittsburgh, PA USA
[16] Natl Canc Inst, Div Canc Treatment Diag, Bethesda, MD USA
[17] Natl Canc Inst, Canc Therapy Evaluat Program, Bethesda, MD USA
[18] H Lee Moffitt Canc Ctr Res Inst, Surg Oncol, Magnolia Campus, Tampa, FL USA
[19] UCLA, Jonsson Comprehens Canc Ctr, Dept Med, Los Angeles, CA USA
[20] Univ Texas MD Anderson Canc Ctr Houston, Dept Pathol, Houston, TX USA
关键词
D O I
10.1016/j.annonc.2023.10.042
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
LBA48
引用
收藏
页码:S1288 / S1288
页数:1
相关论文
empty
未找到相关数据